Clinical trials in systemic lupus erythematosus (SLE): lessons from the past as we proceed to the future – the EULAR recommendations for the management of SLE and the use of end-points in clinical trials

Abstract

Among rheumatic diseases, lupus, especially nephritis, has been more extensively studied with several controlled clinical trials as reported in the literature. The large number of studies on the diagnosis and management of the disease have created a plethora of data that need to be systemically reviewed and formulated in recommendations to be used in daily practice. Moreover, the increasing number of new agents holding the promise of improved efficacy and safety profiles over traditional treatments in systemic lupus erythematosus (SLE) has provided the impetus for optimal design of clinical trials. To this end, and under the auspices of European League Against Rheumatism (EULAR), we developed recommendations for the management of SLE and for points to consider in the design of SLE trials. These recommendations were developed using a combination of research-based evidence following a systematic literature search of trials and cohort studies, and expert consensus. Twelve statements concerning the management of SLE and points regarding the eligibility criteria and outcome measures to be included in trials were developed and are briefly reviewed here. The literature search showed that there have been few high quality Randomized controlled trails (RCTs) in SLE, particularly for manifestations other than nephritis and thus, several important issues have not been adequately addressed. Importantly, end-points currently used in SLE trials have not actually been validated in clinical trials. These findings underscore the need to establish international networks to facilitate clinical trials addressing these issues and testing new therapies.

Get full access to this article

View all access options for this article.

References

1 Jonsson H Nived O Sturfelt G Silman A . Estimating the incidence of systemic lupus erythematosus in a defined population using multiple sources of retrieval. Br J Rheumatol 1990; 29: 185 – 188 .

2 Bertsias GK; Ioannidis JP; Boletis J; . EULAR recommendations for the management of Systemic Lupus Erytematosus (SLE). Report of a Task Force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)*. Ann Rheum Dis 2008; 67: 195–205.

3 Gordon C Bertsias GK Ioannidis JP . EULAR recommendations for points to consider in conducting clinical trials in Systemic Lupus Erythematosus (SLE). Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2008.

4 Ioannidis JP Evans SJ Gotzsche PC . Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med 2004; 141: 781 – 788 .

5 Boumpas DT Austin HA Vaughn EM . Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992; 340: 741 – 745 .

6 Houssiau FA Vasconcelos C D'Cruz D . Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum 2004; 50: 3934 – 3940 .

7 Illei GG Austin HA Crane M . Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001; 135: 248 – 257 .

8 Gourley MF Austin HA Scott D . Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 1996; 125: 549 – 557 .

9 Illei GG Takada K Parkin D . Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum 2002; 46: 995 – 1002 .

10.

10 Mok CC Ying KY Tang S . Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis Rheum 2004; 50: 2559 – 2568 .

11.

11 Barile-Fabris L Ariza-Andraca R Olguin-Ortega L . Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis 2005; 64: 620 – 625 .

12.

12 Abu-Shakra M Mader R Langevitz P . Quality of life in systemic lupus erythematosus: a controlled study. J Rheumatol 1999; 26: 306 – 309 .

13.

13 Doria A Rinaldi S Ermani M . Health-related quality of life in Italian patients with systemic lupus erythematosus. II. Role of clinical, immunological and psychological determinants. Rheumatology (Oxford) 2004; 43: 1580 – 1586 .

14.

14 Fortin PR Abrahamowicz M Neville C . Impact of disease activity and cumulative damage on the health of lupus patients. Lupus 1998; 7: 101 – 107 .

15.

15 Gilboe IM Kvien TK Husby G . Health status in systemic lupus erythematosus compared to rheumatoid arthritis and healthy controls. J Rheumatol 1999; 26: 1694 – 1700 .

16.

16 Gladman DD Urowitz MB Ong A Gough J MacKinnon A . Lack of correlation among the 3 outcomes describing SLE: disease activity, damage and quality of life. Clin Exp Rheumatol 1996; 14: 305 – 308 .

17.

17 Hanly JG . Disease activity, cumulative damage and quality of life in systematic lupus erythematosus: results of a cross-sectional study. Lupus 1997; 6: 243 – 247 .

18.

18 Lassere MN Johnson KR Boers M . Standardized assessment of adverse events in rheumatology clinical trials: summary of the OMERACT 7 drug safety module update. J Rheumatol 2005; 32: 2037 – 2041 .